BEAM — Beam Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.96bn
- $1.11bn
- $63.52m
Annual income statement for Beam Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.024 | 51.8 | 60.9 | 378 | 63.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 133 | 444 | 399 | 554 | 479 |
| Operating Profit | -133 | -392 | -338 | -176 | -416 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -195 | -371 | -260 | -131 | -377 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -195 | -371 | -264 | -133 | -377 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -195 | -371 | -289 | -133 | -377 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -196 | -371 | -289 | -133 | -377 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.19 | -5.77 | -4.13 | -1.72 | -4.58 |